Entero Therapeutics, Inc. - ROE
ENTO
Price:
$2.85
Market Cap:
$18.15M
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic candidates: latiglutenase, an oral biotherapeutic formulated to break down gluten into non-immunogenic peptides for celiac disease patients; adrulipase, a recombinant lipase enzyme engineered to facilitate the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist aimed at addressing gastroparesis; and niclosamide,...[Read more]
Industry
Biotechnology
IPO Date
2016-10-11
Stock Exchange
NASDAQ
Ticker
ENTO
PE Ratio
[-0.24]
ROE
[-18.69%]
Current Ratio
[0.16]
Dividend Yield
[0%]
Enterprise Value
[20.36M]
Dividend History
The ROE as of June 2026 (TTM) for Entero Therapeutics, Inc. (ENTO) is -18.69%
According to Entero Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -18.69%. This represents a change of 137.00% compared to the average of -7.89% of the last 4 quarters.
Entero Therapeutics, Inc. (ENTO) Historical ROE (quarterly & annually)
How has ENTO ROE performed in the past?
The mean historical ROE of Entero Therapeutics, Inc. over the last ten years is -53.60%. The current -18.69% ROE has changed -65.13% with respect to the historical average. Over the past ten years (40 quarters), ENTO's ROE was at its highest in in the December 2020 quarter at 658.93%. The ROE was at its lowest in in the June 2023 quarter at -474.99%.
Average
-53.60%
Median
-315.61%
Minimum
-533.51%
Maximum
1.24%
Entero Therapeutics, Inc. (ENTO) ROE by Quarter and Year
Discovering the peaks and valleys of Entero Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 8.67%
Maximum Annual ROE = 1.24%
Minimum Annual Increase = -476.38%
Minimum Annual ROE = -533.51%
| Year | ROE | Change |
|---|---|---|
| 2025 | -26.96% | -13.69% |
| 2024 | -31.24% | -92.87% |
| 2023 | -438.39% | -17.83% |
| 2022 | -533.51% | -171.29% |
| 2021 | 748.42% | -39.51% |
| 2020 | 1.24% | -476.38% |
| 2019 | -328.72% | 8.67% |
| 2018 | -302.50% | -25.53% |
| 2017 | -406.21% | -10.55% |
| 2016 | -454.14% | -377.98% |
Entero Therapeutics, Inc. (ENTO) Average ROE
How has ENTO ROE performed in the past?
The current ROE of Entero Therapeutics, Inc. (ENTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-165.53%
5-year avg
-56.34%
10-year avg
-53.60%
Entero Therapeutics, Inc. (ENTO) ROE vs. Peers
How is ENTO’s ROE compared to its peers?
Entero Therapeutics, Inc.’s ROE is less than Curis, Inc. (805.67%), greater than Processa Pharmaceuticals, Inc. (-281.30%), greater than BriaCell Therapeutics Corp. (-147.92%), greater than Palisade Bio, Inc. (-36.79%), greater than Citius Pharmaceuticals, Inc. (-67.42%), greater than Leap Therapeutics, Inc. (-46.86%), less than Aspire Biopharma Holdings, Inc. (199.43%), greater than Athira Pharma, Inc. (-381.01%), greater than Cingulate Inc. (-365.16%), greater than Allarity Therapeutics, Inc. (-109.94%),
| Company | ROE | Market cap |
|---|---|---|
| 805.67% | $5.54M | |
| -281.30% | $4.80M | |
| -147.92% | $5.46M | |
| -36.79% | $324.59M | |
| -67.42% | $6.11M | |
| -46.86% | $31.86M | |
| 199.43% | $759.15K | |
| -381.01% | $26.62M | |
| -365.16% | $27.97M | |
| -109.94% | $22.75M |
Build a custom stock screener for Entero Therapeutics, Inc. (ENTO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entero Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Entero Therapeutics, Inc. (ENTO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Entero Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Entero Therapeutics, Inc.'s ROE?
How is the ROE calculated for Entero Therapeutics, Inc. (ENTO)?
What is the highest ROE for Entero Therapeutics, Inc. (ENTO)?
What is the 3-year average ROE for Entero Therapeutics, Inc. (ENTO)?
What is the 5-year average ROE for Entero Therapeutics, Inc. (ENTO)?
How does the current ROE for Entero Therapeutics, Inc. (ENTO) compare to its historical average?